Breast Cancer Clinical Trial Overview

SCCA Breast Cancer Clinical Trials

F-18 FES PET in Measuring Hormone Expression (7184)
Serial [F-18] fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy
Status Conditions Phase Study ID
Recruiting Breast Cancer N/A 7184

This clinical trial studies F-18 16 alpha-fluoroestradiol (F-18 FES) positron emission tomography (PET) in measuring hormone expression in patients with recurrent or metastatic breast cancer undergoing endocrine-targeted therapy. Comparing results of diagnostic procedures done before, during, and after hormone therapy may help measure a patient's response to treatment.

Hannah Linden, MD
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Adult, non-pregnant patients with biopsy-proven or clinically obvious primary, recurrent or metastatic breast cancer
  • Breast cancer from ER+ primary that is seen on other imaging tests; tumor ER expression must have been confirmed by immunohistocytochemistry of primary tumor or recurrent disease
  • At least one site of disease 1.5 cm or greater is needed to meet the spatial resolution limits of PET imaging
  • Patients must have been off tamoxifen or other estrogen receptor blocking agents for at least 6 weeks and off chemotherapy for 3 weeks for the initial baseline FES
  • Patients must be selected for an endocrine targeted therapy regimen for treatment of their breast cancer by the referring oncologist; selected treatments may be part of experimental treatment protocols for which the patient would be separately consented
  • Patients must be willing to undergo serial imaging procedures
  • Patients must agree to allow access to clinical records regarding response to treatment and long term follow up
Exclusions (conditions that would prevent participation in this study)
  • An inability to lie still for the tests
  • Individuals weighing more than 300 lb; (this is the weight limit of the scanner table)
  • Pregnant or lactating; women of childbearing potential with either a positive or no pregnancy test at baseline are excluded
  • Any other life-threatening illness (e.g. serious, uncontrolled concurrent infection or clinically significant cardiac disease - congestive heart failure, symptomatic coronary artery disease, cardiac arrhythmia not well controlled with medication)
  • Use of tamoxifen, Faslodex, diethylstilbestrol (DES) or any other ER blocking agent < 6 weeks or chemotherapy < 3 weeks prior to imaging scan
  • Unwillingness or inability to give informed consent
  • Uncontrolled diabetes mellitus (fasting glucose > 200 mg/dL)
  • Adult patients who require monitored anesthesia for PET scanning
Last Updated
June 11, 2014
See this trial at
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.